The Bladder Cancer Company

About Us

Our Values

Our History

Bladder cancer challenge

Board of directors

Executive Leadership

Leadership

Our Company

Photocure Technology

Our products

Research support

Innovation & Products

News

Bladder Cancer and AI

Addressing Inequality

Our Perspective

Patient Registries And Real-World Evidence

Bladder cancer community support

Corporate social responsibility

ESG Report

Our Impact

Why Partner with Photocure

Our Partners

Partners

Photocure culture

Working at Photocure

Careers

Contact

Events & Presentations

Financials

Shareholder information

FAQs

Investors hub

Investors

Press & Media

Privacy Policy

Terms of use

cevira

<p class="spacer"><br></p>
<h1>Shareholders</h1>
<p class="spacer"><br></p>

thumbnail_ShareHolderInfo@2x.png

ESG report

Photocure Partner Asieris Unveils Cevira (APL-1702) Phase III Subgroup Analysis by Age Groups at the 2024 CSCO Annual Meeting

Photocure establishes Named Patient Program to provide access to Hexvix in South Africa

Product Announcements

Partnership News & Expansion

Cevira (APL-1702): Photocure Partner Asieris Unveils Efficacy Data of Non-Surgical Treatment of Cervical HSIL at the 2024 PDT&PD Conference

Medical congresses & events

Medical Information

New publication: blue light cystoscopy shows potential to facilitate the diagnosis of CIS in the upper urinary tract

Photocure ASA: Results for the second quarter of 2024

Financial Investment & Stock

Photocure ASA: Invitation to presentation of second quarter and first half year 2024 financial results

Photocure and Richard Wolf Enter into Agreement to Develop a High-Definition Flexible Blue Light Cystoscope for Global Commercialization

New Photocure White Paper:  Beyond the buzzwords – How AI and advancing diagnostic technologies will transform early bladder cancer care

Real World Evidence

Photocure Announces Mobile BLC Tower Initiative to Expand Access to Cysview in the U.S.

Organisational Announcements

Photocure ASA – Annual general meeting held

Photocure ASA: Results for the first quarter of 2024

Photocure Partner Asieris announces New Drug Application acceptance for regulatory review of Cevira in China

Photocure ASA: Invitation to presentation of first quarter 2024 financial results

Bladder Cancer: Long-Term Benefits of Blue Light Cystoscopy and Enhanced Detection with HD Technology Unveiled at AUA 2024

Photocure ASA – Notice of the Annual General Meeting 23 May 2024

Photocure ASA: Annual Report 2023

<p>We use cookies to provide the best possible experience for you. By closing this message you agree to our use of cookies. You can learn more about cookies on our <a href="https://photocure.com/privacy-policy" target="_blank" rel="nofollow noopener noreferrer">privacy page</a>.</p>

agree

Shareholders

Investor news

E-mail: info@photocure.no

E-mail: info@photocure.com

E-mail: kontakt@photocure.com